

Synthesis and assignment of the absolute configuration of the anti-*Helicobacter pylori* agents CJ-12,954 and CJ-13,014†

Margaret A. Brimble* and Christina J. Bryant

Received 29th June 2007, Accepted 13th July 2007

First published as an Advance Article on the web 31st July 2007

DOI: 10.1039/b709932k

The synthesis of the spiroacetal-containing anti-*Helicobacter pylori* agents (3*S*,2''*S*,5''*S*,7''*S*)-**1a** (*ent*-CJ-12,954) and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** (*ent*-CJ-13,014) has been carried out based on the convergent union of a 1 : 1 mixture of heterocycle-activated spiroacetal sulfones **6** and **7** with (3*S*)-phthalide aldehyde **5a**. The synthesis of the (3*R*)-diastereomers (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b** was also undertaken in a similar manner by union of (3*R*)-phthalide aldehyde **5b** with a 1 : 1 mixture of spiroacetal sulfones **6** and **7**. Comparison of the ¹H and ¹³C NMR data, optical rotations and HPLC retention times of the synthetic compounds (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** and the (3*R*)-diastereomers (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b**, with the naturally occurring compounds, established that the synthetic isomers **1a** and **2a** were in fact enantiomeric to the natural products CJ-12,954 and CJ-13,014. The (2*S*,8*S*)-stereochemistry in protected dihydroxyketone **21**, the precursor to the mixture of spiroacetal sulfones **6** and **7** was established *via* union of readily available (*S*)-acetylene **18** with aldehyde **17** in which the (4*S*)-stereochemistry was established *via* asymmetric allylation. Deprotection and cyclization of protected dihydroxyketone **21** afforded an inseparable 1 : 1 mixture of spiroacetal alcohols **24** and **25** that were converted into a 1 : 1 inseparable mixture of spiroacetal sulfones **6** and **7**. Phthalide-aldehyde **3a** was prepared *via* intramolecular acylation of bromocarbamate **11** in which the (3*S*)-stereochemistry was established *via* asymmetric CBS reduction of ketone **8**.

Introduction

Helicobacter pylori are microaerophilic, Gram negative bacteria¹ which colonize the stomach of over half the world's population² and have an etiological role in several diseases including gastric and duodenal ulcers, distal gastric cancer and MALT lymphoma.³ In most cases infection will persist for the lifetime of an individual without medical intervention.⁴ A variety of effective drugs for the treatment and eradication of *Helicobacter pylori* infection are clinically useful including antibiotics (β -lactams, macrolides and quinolones), bactericidal agents (bismuth salts) and anti-protozoal agents (metronidazole); however, drug resistance, side effects and non-compliance are common problems in the use of such drugs.⁵ Current treatment of *Helicobacter pylori* infection involves the prescription of one or more antibiotics in combination with H₂ blockers; however, none of the existing treatments are capable of complete eradication of *Helicobacter pylori*.⁶ Consequently, there is an urgent need for the development of more effective and selective anti-*Helicobacter pylori* agents.

In a screening program designed to discover such compounds, Dekker *et al.*⁷ isolated seven new 5,7-dimethoxyphthalide antibiotics with specific anti-*Helicobacter pylori* activity from the basidiomycete *Phanerochaete velutina* CL6387. The two most

potent compounds CJ-12,954 **1** and its C-5'' epimer CJ-13,014 **2** contained a 5,5-spiroacetal ring joined through a polymethylene chain to the phthalide unit (Fig. 1). While changes in the stereochemistry associated with the spiroacetal has little effect on antibacterial activity, the diketone formed by ring opening exhibits a decreased potency of approximately 100-fold. Two structurally related helicobactericidal compounds, spiroloxine **3** and its methyl ether **4**, produced by various strains of white rot fungi belonging to the genera *Sporotrichum* and *Phanerochaete*, contain a 6,5-spiroacetal ring joined through a polymethylene




Fig. 1 Structures of anti-*Helicobacter pylori* agents.

Department of Chemistry, University of Auckland, 23 Symonds St., Auckland, New Zealand. E-mail: m.brimble@auckland.ac.nz; Fax: +64 9 3737422

† Electronic supplementary information (ESI) available: General experimental details together with full experimental procedures, ¹H NMR, ¹³C NMR and mass spectral data for compounds **5a**, **8–21**, **30** and **31**. See DOI: 10.1039/b709932k

chain to a phthalide unit.⁸ Thus, phthalide-containing spiroacetal compounds provide promising new leads for the treatment of *Helicobacter pylori* related diseases.


Whilst Dekker *et al.*⁷ were unable to assign the stereochemistry of the stereogenic centre at C-3 on the phthalide unit in CJ-12,954 **1** and CJ-13,014 **2**, they were able to assign the relative stereochemistry of the three stereogenic centres on the spiroacetal ring. CJ-12,954 **1** was assigned with 1,3-*syn* stereochemistry between the C2''-Me group and the C5''-O6'' bond with the 6'-CH₂ group 1,3-*syn* to C5''-O1''. In the case of CJ-13,014 **2** the C2''-Me group was assigned as 1,3-*anti* to the C5''-O6'' bond with the 6'-CH₂ group 1,3-*anti* to the C5''-O1'' bond. The structures of CJ-12,954 **1** and CJ-13,014 **2** were initially arbitrarily depicted with the (*S*)-configuration at both C2'' and C7'' however, the assignment of absolute stereochemistry to these stereogenic centres in the spiroacetal ring and at C-3 on the phthalide unit is reliant on the execution of a total synthesis of these natural products.

Whilst a synthesis of the phthalide-spiroacetals CJ-12,954 **1** and CJ-13,014 **2** has not been reported to date, several of the simpler non spiroacetal-containing phthalides have been prepared with lack of stereocontrol of the phthalide unit.⁹⁻¹¹ We have previously reported¹² the first enantioselective total synthesis of (+)-spiroloxine methyl ether **4** that established the absolute configuration of the natural product to be (3*R*,2''*R*,5''*R*,7''*R*). This conclusion was later confirmed by single-crystal X-ray analysis¹³ of spiroloxine **3** and an independent synthesis of spiroloxine methyl ether **4**.¹⁴ We now herein report the full details¹⁵ of our synthesis of the anti-*Helicobacter pylori* agents (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** and the (3*R*)-diastereomers (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b** thereby establishing that the synthetic isomers **1a** and **2a** were in fact enantiomeric to the natural products CJ-12,954 and CJ-13,014.


Results and discussion

Given that the absolute stereochemistry of the four stereogenic centres in CJ-12,954 **1** and CJ-13,014 **2** had not been assigned, it was important to develop a flexible modular approach that would allow variation in the construction of the stereogenic centres in these molecules. Our attention initially focused on the synthesis of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** arbitrarily chosen with an (*S*)-configuration at C-3 on the phthalide unit and an (*S*)-configuration at both C-2'' and C-7'' on the spiroacetal unit (Scheme 1). It was envisaged that control of the stereochemistry of the spirocentre in the 5,5-spiroacetal ring system would be more difficult hence our efforts were directed to the synthesis of a 1 : 1 mixture of heterocycle-activated sulfones **6** and **7** in preparation for union with (3*S*)-phthalide-aldehyde **5a** using a modified Julia-Kocienski olefination.

The synthesis of (3*S*)-phthalide-aldehyde **5a** hinged on the initial synthesis of (*S*)-alcohol **9** that undergoes regioselective bromination to bromide **10** and conversion to bromocarbamate **11** (Scheme 2). Carbamate **11** is then transformed into phthalide-aldehyde **5a** via intramolecular acylation and hydroboration-oxidation of the olefin. Whilst the efficacy of the latter steps had been readily demonstrated¹² in the enantiomeric series to prepare (3*R*)-phthalide-aldehyde **5b** the synthesis of (*S*)-alcohol **9** in high enantiopurity needed attention. For the synthesis of (3*R*)-



Scheme 1 Retrosynthesis of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a**.



Scheme 2 Reagents and conditions: (i) (*R*)-Me-CBS-oxazaborolidine (CBS = Corey-Bakshi-Shibata), BH₃-SMe₂, 15 min, then THF, **8**, 2 h, 92%, 94% ee; (ii) NBS, NH₄OAc, Et₂O, 24 h, 90%; (iii) NaH, THF, 0 °C then *N,N*-diethylcarbonyl chloride, 90%; (iv) *t*-BuLi, THF, -78 °C, 2 h then camphorsulfonic acid, 20 °C, 12 h, 70%; (v) 2-methyl-2-butene, BH₃-SMe₂, THF, 0 °C then MeOH, NaOH, 30% H₂O₂, 71%; (vi) TPAP, NMO, CH₂Cl₂, 4 Å mol. sieves, 6 h, 20 °C, 72%.

phthalide-aldehyde **5b** the (*R*)-enantiomer of alcohol **9** was established *via* asymmetric allylation of 3,5-dimethoxybenzaldehyde for which the optimal enantiomeric excess (ee) obtained was only 86%. We therefore decided to investigate an asymmetric reduction procedure to prepare (*S*)-alcohol **9** in the present work.


Asymmetric reduction of ketone **8** using (–)-DIP-Cl in THF at -35 °C following the procedure reported by Wang *et al.*¹⁶ afforded (*S*)-alcohol **9** in only 40% yield with 92% ee. Fortunately, reduction of ketone **8** with (*R*)-2-methyl-CBS-oxazaborolidine¹⁷ (1.0 equiv.) and borane-dimethyl sulfide (1.0 equiv.) in THF at -20 °C for 2 h afforded (*S*)-alcohol **9** in higher 92% yield with an improved 94%

ee as determined by conversion to a Mosher ester derivative. It was noted that if an excess of borane–dimethyl sulfide relative to (*R*)-2-methyl-CBS-oxazaborolidine was used then rearrangement of the β,γ -unsaturated ketone to the more stable α,β -unsaturated ketone occurred with none of the desired alcohol **9** being formed.

With a facile synthesis of (*S*)-alcohol **9** in hand, conversion to (3*S*)-phthalide-aldehyde **5a** proceeded uneventfully *via* bromination to bromide **10**, formation of carbamate **11** using sodium hydride and *N,N*-diethylcarbamoyl chloride followed by internal

acylation of the derived *ortho*-lithiated species formed upon halogen–metal exchange to afford phthalide **12**. Hydroboration of the olefin and subsequent oxidation using tetrapropylammonium perruthenate and *N*-methylmorpholine-*N*-oxide secured (3*S*)-phthalide-aldehyde **5a**.¹¹

Our attention next focused on the synthesis of 1-phenyl-1*H*-tetrazol-5-yl spiroacetal sulfones **6** and **7** that are epimeric at the spirocentre with an (*S*)-configuration at C-2'' and C-7'' (Scheme 3). The synthesis of (2*S*,5*S*,7*S*)-spiroacetal **6** and



Scheme 3 Reagents and conditions: (i) allyl bromide, Mg, (+)- β -diisopinocampheylmethoxyborane, Et₂O, -78 °C to 20 °C, 82%, 94% ee; (ii) ^tBuMe₂SiCl, imidazole, DMAP, CH₂Cl₂, 20 °C, 12 h, 90%; (iii) 2-methyl-2-butene, BH₃·SMe₂, 0 °C, 76%; (iv) Dess–Martin periodinane, py, CH₂Cl₂, 20 °C, 77%; (v) **18**, *n*-BuLi, LiBr, THF, -78 °C, then **17**, 84%; (vi) TPAP, NMO, 4 Å mol sieves, CH₂Cl₂, 20 °C, 94%; (vii) H₂, PtO₂, K₂CO₃, THF–MeOH (1 : 1), 94%; (viii) CSA, CH₂Cl₂, 20 °C, 4 h, 93%; (ix) TBAF, CH₂Cl₂, 20 °C, 3 h, 77%; (x) 1-phenyl-1*H*-tetrazole-5-thiol, Ph₃P, DEAD, 78%; (xi) *m*-CPBA, NaHCO₃, 71%; (xii) KHMDS, THF, -78 °C then **5a**, 84%; (xiii) H₂, PtO₂, K₂CO₃, THF–MeOH (1 : 1), 85%.

(2*S*,5*R*,7*S*)-spiroacetal **7** was arbitrarily pursued due the ready availability of 3-butyn-1-ol **18**¹⁸ with (*S*)-absolute stereochemistry that upon conversion to the corresponding lithium (*S*)-acetylide leads to the 5,5-spiroacetal ring system with (*S*)-stereochemistry at C-2'. The corresponding (*S*)-stereochemistry at C-7'' in the 5,5-spiroacetal ring system is derived from homoallylic alcohol **14** that is available *via* asymmetric allylation of aldehyde **13**. Importantly, 1-phenyl-1*H*-tetrazol-5-yl sulfones **6** and **7** were chosen in preference to the use of benzothiazol-2-yl sulfones due to their increased stability in heterocycle-modified Julia olefinations.^{19,20}

Addition of allylmagnesium bromide to (+)- β -diisopinocampheylmethoxyborane in diethyl ether at -78°C followed by addition to aldehyde **13**²¹ afforded (*S*)-alcohol **14** in 82% yield after peroxide work-up for which the ee was determined to be 94% by chiral HPLC. (*S*)-Alcohol **14** has previously been prepared by an alternative procedure however the ee was not determined in this case.²² The (*R*)-enantiomer of alcohol **14** has also been prepared previously in 74% ee using a tartaric acid derived allylboration.²³ Gratifyingly, the asymmetric reduction method reported herein offers a significant improvement on existing methods to prepare this compound enantioselectively. Protection of the alcohol as a *tert*-butyldimethylsilyl ether **15** followed by hydroboration to primary alcohol **16** the oxidation using Dess–Martin periodinane afforded aldehyde **17**.


Addition of aldehyde **17** to the lithium acetylide of **18** at -78°C and at -100°C initially proved problematic with only low yields of the desired alcohol **19** being obtained. Due to the continual recovery of starting materials along with the coupled product **19** it was postulated that enolate formation was occurring in preference to the desired nucleophilic addition reaction. Brandsma *et al.*²⁴ and Carreira *et al.*²⁵ have incorporated the use of lithium bromide to prevent a similar problem in the reaction of lithium acetylides with ketones. In the present case reaction of aldehyde **17** with the lithium acetylide of **18** in tetrahydrofuran at -78°C , with the inclusion of 50 mol% of lithium bromide, proceeded cleanly furnishing alcohol **19** as a mixture of diastereomers in 84% yield.

Oxidation of the alcohol **19** to ynone **20** using tetrapropylammonium perruthenate and *N*-methylmorpholine-*N*-oxide followed by reduction of the acetylene over Adams's catalyst (PtO_2) afforded saturated protected dihydroxyketone **21**. Spirocyclization was then readily effected in 93% yield using camphorsulfonic acid in dichloromethane affording an inseparable 1 : 1 mixture of spiroacetals **22** and **23** that were converted into spiroacetal alcohols **24** and **25** after cleavage of the *tert*-butyldiphenylsilyl ether with tetrabutylammonium fluoride. Lack of stereocontrol from the anomeric effect and/or steric effects contributed to the observed formation of equal quantities of 5,5-spiroacetals **24** and **25** with (*S*)- and (*R*)-stereochemistry at the spirocentres, respectively. For spirocyclizations involving two five-membered rings a strong anomeric effect was not expected due to lack of well-defined axial or equatorial positions in these systems.²⁶

In the ^1H NMR spectrum for the mixture of spiroacetals **24** and **25**, resonances at δ 4.05 (dddd, J 10.7, 8.7, 4.9, 2.2 Hz) and δ 4.19 (qdd, J 6.4, 6.4, 2.2 Hz), corresponding to H7 and H2 respectively, displayed multiplicities that were indicative of cyclic ring formation. Two doublets at δ 1.21 and δ 1.30 (J 6.2 Hz) of equal intensity, were assigned to the individual methyl groups of each spiroacetal alcohol. Further support for the successful

formation of spiroacetal alcohols **24** and **25** was the observation of two quaternary carbon resonances in the ^{13}C NMR spectrum at δ 114.3 and δ 114.7 which were characteristic of 5,5 spiroacetal carbons. A molecular ion at m/z 201.1490 in the high resolution CI mass spectrum (201.1491 calculated for MH^+) provided further evidence for the successful formation of the spiroacetal alcohols **24** and **25**.

With phthalide-aldehyde **5a** and spiroacetal alcohols **24** and **25** in hand, attention turned to their union to form the carbon skeleton of CJ-12,952 and CJ-13,014. Use of benzothiazol-2-yl sulfones **30** and **31** as coupling partners for the modified Julia–Kocienski olefination proved disappointing with only low yields of the desired coupled olefins **28** and **29** being obtained (Scheme 4). The low yield obtained in the reaction was attributed to the instability of the benzothiazol-2-yl sulfone. The self-condensation of the benzothiazol-2-yl sulfones has been well documented in the literature²⁷ hence we turned our efforts to the use of the more stable 1-phenyl-1*H*-tetrazol-5-yl sulfones developed by Kocienski *et al.*²⁰ There are no literature reports on the use of a spiroacetal-containing 1-phenyl-1*H*-tetrazol-5-yl sulfone in a modified Julia olefination. However, Bondar and Paquette²⁸ have reported the addition of a 1-phenyl-1*H*-tetrazol-5-yl sulfone to a spiroacetal-containing aldehyde in their synthetic studies towards pectenotoxin-2.



Scheme 4 Reagents and conditions: (i) KHMDS, THF, -78°C then **5a**, -78°C , 1.1 h, warm to room temp., 1 h, 19%.

Triphenylphosphine, 1-phenyl-1*H*-tetrazol-5-thiol, and diethyl azodicarboxylate were added to a solution of spiroacetal alcohols **24** and **25** in tetrahydrofuran at 0°C , then stirred at room temperature for 15 h to yield sulfides **26** and **27** (Scheme 3). Sulfides **26** and **27** were then treated with *m*-chloroperoxybenzoic acid and sodium bicarbonate in dichloromethane at room temperature for 24 h to afford sulfones **6** and **7** in excellent yield.

Attention next focused on the union of sulfones **6** and **7** with (3*S*)-phthalide-aldehyde **5a** (Scheme 3). Potassium hexamethyldisilazide was added to a solution of sulfones **6** and **7** in tetrahydrofuran at -78°C and the mixture stirred for 20 min. (3*S*)-Phthalide-aldehyde **5a** was then added and the mixture stirred for 90 min at -78°C , then warmed to room temperature for 1 h to afford a mixture of alkenes **28** and **29** in 84% yield. The ratio of (*E*)- and (*Z*)-alkenes **28** and **29** obtained from this reaction was not determined. Finally hydrogenation of the mixture of alkenes **28** and **29** over Adams' catalyst (PtO_2) in tetrahydrofuran–methanol (1 : 1) in the presence of potassium carbonate at room temperature for 4 h afforded an inseparable 1 : 1 mixture of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** in 85% yield after purification by flash chromatography.

Characteristic resonances at δ 114.3 and 114.7 assigned to C5'' in (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a**, respectively, supported the presence of the 5,5-spiroacetal ring system. The




Fig. 2

^1H NMR spectrum displayed two doublets at δ 1.20 and 1.28 ppm (J 6.2 Hz) assigned to the methyl group in (3*S*,2''*S*,5''*R*,7''*S*)-**2a** and (3*S*,2''*S*,5''*S*,7''*S*)-**1a**, respectively, in good agreement with the data for the natural products (Fig. 2). A doublet of doublets at δ 5.29 ppm (J 8.2, 3.7 Hz) was assigned to H3 in the phthalide moiety with the chemical shift at variance with the chemical shift reported for the same resonance at δ 5.27 (dd, J 8.1, 3.7 Hz) in the natural products CJ-12,954 **1** and CJ-13,014 **2**.⁷

Due the ready availability of (3*R*)-phthalide-aldehyde **5b** within our research group¹² we also prepared the closely related phthalide-spiroacetals **1b** and **2b** with (3*R*)-stereochemistry on the phthalide (Scheme 5). Thus, olefination of (3*R*)-phthalide-aldehyde **5b** with a 1 : 1 mixture of sulfones **6** and **7** followed by hydrogenation of the resultant olefins **32** and **33** afforded a 1 : 1 mixture of (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b**. Frustratingly, the ^1H and ^{13}C NMR data obtained for these latter isomers was similar to that recorded for both synthetic isomers **1a** and **2a** and the respective natural products (Fig. 2).


Unfortunately, separation of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** from each other, and (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b** from each other proved exceedingly difficult. Use of column chromatography, thin layer chromatography and normal phase HPLC did not facilitate separation of the individual diastereomers. A small sample of pure (3*R*,2''*S*,5''*R*,7''*S*)-**2b** was successfully isolated after repeated use of flash column chromatography, however, no other diastereomer was able to be completely separated from its corresponding 5''-epimer.

The key ^1H NMR and ^{13}C NMR data observed for (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*R*,2''*S*,5''*S*,7''*S*)-**1b** proved to be very similar to that obtained by Dekker *et al.*⁷ for the natural product

CJ-12,954 **1**. (Fig. 2). For example, the methyl group on the spiroacetal ring in the natural product CJ-12,954 **1** resonated at δ_{H} 1.27 ppm (d, J 6.2 Hz) in the ^1H NMR spectrum and δ_{C} 23.0 ppm in the ^{13}C NMR spectrum. For (3*S*,2''*S*,5''*S*,7''*S*)-**1a** the methyl group resonated at δ_{H} 1.28 ppm (d, J 6.2 Hz) and δ_{C} 23.0 ppm, whilst in (3*R*,2''*S*,5''*S*,7''*S*)-**1b** the methyl group resonated at δ_{H} 1.26 ppm (d, J 6.2 Hz) in the ^1H NMR spectrum and at δ_{C} 22.9 ppm in the ^{13}C NMR spectrum.

Likewise, the key ^1H NMR and ^{13}C NMR data for (3*S*,2''*S*,5''*R*,7''*S*)-**2a** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b** was almost identical to the data reported by Dekker *et al.*⁷ for the natural product CJ-13,014 **2**. (Fig. 2). For example, the methyl group on the spiroacetal in the natural product CJ-13,014 **2** resonated at δ_{H} 1.19 ppm (d, J 6.2 Hz) in the ^1H NMR spectrum and at δ_{C} 21.1 ppm in the ^{13}C NMR spectrum. For (3*S*,2''*S*,5''*R*,7''*S*)-**2a** the methyl group resonated at δ_{H} 1.20 ppm (d, J 6.2 Hz) in the ^1H NMR spectrum and at δ_{C} 21.1 ppm in the ^{13}C NMR spectrum, and for (3*R*,2''*S*,5''*R*,7''*S*)-**2b** the methyl group resonated at δ_{H} 1.21 ppm (d, J 6.2 Hz) in the ^1H NMR spectrum and at δ_{C} 21.1 ppm in the ^{13}C NMR spectrum.

The 1 : 1 mixture of synthetic (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a**, and the 1 : 1 mixture of synthetic (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b**, were analysed by HPLC, using the same conditions (YMC-Pack ODS-AM column, methanol : water (3 : 1), flow rate 0.5 mL min⁻¹) reported by Dekker *et al.*⁷ for the separation of the natural products CJ-12,954 **1** and CJ-13,014 **2**. Pure samples of the natural products CJ-12,954 **1** and CJ-13,014 **2**, obtained from Pfizer Inc., were also analysed under the same HPLC conditions. The retention time for the natural product CJ-12,954 **1** was 8.7 min, and the



Scheme 5 Reagents and conditions: (i) KHMDS, THF, -78 °C then **5b**, 76%; (ii) H₂, PtO₂, K₂CO₃, THF-MeOH (1 : 1), 90%.

retention time for the natural product CJ-13,014 **2** was 9.4 min. The retention times for the 1 : 1 mixture of synthetic (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** were 8.7 and 9.4 min, respectively. The retention times for the 1 : 1 mixture of synthetic (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b** were 9.2 and 9.6 min. Thus, the retention times observed for the natural CJ-12,954 **1** and CJ-13,014 **2** were identical to the retention times for the synthetic mixture of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a**. Additionally, the ¹H and ¹³C NMR data is very similar for natural CJ-12,954 **1** and synthetic (3*S*,2''*S*,5''*S*,7''*S*)-**1a**, and for natural CJ-13,014 **2** and synthetic (3*S*,2''*S*,5''*R*,7''*S*)-**2a**.

The optical rotation for the natural product CJ-12,954 **1** was reported in the literature as +6.0 (*c* 0.07, CHCl₃), whereas the optical rotation for the natural product CJ-13,014 **2** was reported as +71.2 (*c* 0.11, CHCl₃).⁷ Due to the inability to separate (3*S*,2''*S*,5''*S*,7''*S*)-**1a** from (3*S*,2''*S*,5''*R*,7''*S*)-**2a**, the optical rotation was recorded for the 1 : 1 mixture of these two diastereomers as -38.0 (*c* 0.48, CHCl₃). An optical rotation of +36.4 (*c* 0.50, CHCl₃) was obtained for the 1 : 1 mixture of (3*R*,2''*S*,5''*S*,7''*S*)-**1b** and (3*R*,2''*S*,5''*R*,7''*S*)-**2b**. Given that the optical rotation for the 1 : 1 mixture of (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and (3*S*,2''*S*,5''*R*,7''*S*)-**2a** is of opposite sign and an average of the optical rotation values reported for the natural products CJ-12,954 **1** and CJ-13,014 **2**, it is therefore proposed that naturally occurring CJ-12,954 **1** exhibits (3*R*,2''*R*,5''*R*,7''*R*)-stereochemistry (*ent*-**1a**) and

natural CJ-13,014 **2** exhibits (3*R*,2''*R*,5''*S*,7''*R*)-stereochemistry (*ent*-**2a**). This assignment would account for the fact that the HPLC retention times observed for synthetic (3*S*,2''*S*,5''*S*,7''*S*)-**1a** and naturally occurring CJ-12,954 **1** were identical since these compounds are in fact enantiomeric to each other. Similarly, the HPLC retention times observed for synthetic (3*S*,2''*S*,5''*R*,7''*S*)-**2a** and naturally occurring CJ-13,014 **2** are also enantiomeric.

In summary the synthesis of the helicobactericidal agents CJ-12,954 and CJ-13,014, namely (3*S*,2''*S*,5''*S*,7''*S*)-(**1a**) and (3*S*,2''*S*,5''*R*,7''*S*)-(**2a**) has been achieved *via* Kocienski modified Julia olefination of (3*S*)-phthalide-aldehyde **5a** with a 1 : 1 mixture of heterocyclic sulfones **6** and **7**. Further complementary synthesis of the (3*R*)-diastereomers (3*R*,2''*S*,5''*S*,7''*S*)-(**1b**) and (3*R*,2''*S*,5''*R*,7''*S*)-(**2b**) facilitated confirmation of the relative stereochemistry between C-3 on the phthalide unit and C5''/C7'' on the 5,5-spiroacetal moiety. The synthetic work herein reported thus establishes unequivocally that the absolute configuration of the four stereogenic centres in the natural product CJ-12,954 is (3*R*,2''*R*,5''*R*,7''*R*) and in CJ-13,014 is (3*R*,2''*R*,5''*S*,7''*R*).

Experimental

(2*S*,5*R*,7*S*) and (2*S*,5*S*,7*R*)-7-(3'-(*tert*-Butyldiphenylsilyloxy)-propyl)-2-methyl-1,6-dioxaspiro[4.4]nonane (**22**) and (**23**)

To a solution of (2*S*,8*S*)-ketone **21** (50 mg, 0.07 mmol) in dichloromethane (3 mL) was added camphorsulfonic acid (35 mg, 0.15 mmol). The solution was stirred for 4 h then filtered through a plug of Celite[®] and the solvent removed under reduced pressure. The crude oil was purified by flash column chromatography using hexane-diethyl ether (95 : 5) as eluent to afford the *title compounds* **22** and **23** (30 mg, 93%) as a clear colourless oil and as a 1 : 1 mixture of two diastereomers; ν_{\max} (film)/cm⁻¹ 2960, 2856, 1472, 1427, 1111, 1008, 822, 739, 701; δ_{H} (300 MHz, CDCl₃)[‡] 1.07 (9H, s, Si^tBuPh₂), 1.23 (1.5H, d, *J* 6.2 Hz, Me), 1.29 (1.5H, d, *J* 6.2 Hz, Me*), 1.43–1.78 (6H, m, H3A, H8A, H2', H3'), 1.91–2.17 (6H, m, H3B, H4, H8B, H9), 3.70 (2H, t, *J* 6.2 Hz, H3'), 4.06–4.13 (1H, m, H7), 4.20 (1H, qd, *J* 6.3, 6.3 Hz, H2), 7.37–7.45 (6H, m, Si^tBuPh₂, *m* and *p*), 7.69 (4H, dd, *J* 7.3, 1.4 Hz, Si^tBuPh₂, *o*); δ_{C} (75.5 MHz, CDCl₃) 19.2 (quat., Si^tBuPh₂), 21.2 (CH₃, Me[‡]), 23.0 (CH₃, Me[♠]), 26.9 (CH₃, Si^tBuPh₂), 29.0 (CH₂, C2'), 29.3 (CH₂, C2'*), 30.2 (CH₂, C8), 30.8 (CH₂, C8*), 32.0 (CH₂, C3), 32.2 (CH₂, C3*), 33.7 (CH₂, C1*), 35.6 (CH₂, C4), 36.1 (CH₂, C9), 36.5 (CH₂, C9*), 63.9 (CH₂, C3'), 74.0 (CH, C2[‡]), 75.8 (CH, C2[♠]), 77.9 (CH, C7), 79.7 (CH, C7[♠]), 114.3 (quat., C5[♠]), 114.7 (quat., C5[‡]), 127.6 (CH, Si^tBuPh₂, *m*), 129.5 (CH, Si^tBuPh₂, *p*), 134.1 (quat., Si^tBuPh₂), 135.6 (CH, Si^tBuPh₂, *o*); *m/z* (CI, NH₃) 439 (MH⁺, 100%), 421 (8), 381 (19), 183 (20), 165 (16); HRMS (CI): Found MH⁺, 439.2665; C₂₇H₃₉O₃Si requires 439.2669.

(2*S*,5*R*,7*S*) and (2*S*,5*S*,7*S*)-7-(3'-Hydroxypropyl)-2-methyl-1,6-dioxaspiro[4.4]nonane (**24**) and (**25**)

To a solution of silyl ethers **22** and **23** (0.31 g, 0.71 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (0.37 g, 1.41 mmol) and the mixture stirred for 3 h. The solution

[‡] The symbol * is used to denote either the (2*S*,5*R*,7*S*) or the (2*S*,5*S*,7*S*) isomer. The symbol [‡] is used to denote the (2*S*,5*R*,7*S*) isomer. The symbol [♠] is used to denote the (2*S*,5*S*,7*S*) isomer.

was diluted with diethyl ether (10 mL) then saturated aqueous sodium bicarbonate (10 mL) was added. The layers were separated and the aqueous layer extracted with diethyl ether (2 × 20 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over potassium carbonate and the solvent removed under reduced pressure. The mixture was purified by flash column chromatography using hexane–diethyl ether (9 : 1–1 : 1) as eluent to yield the *title compounds* **24** and **25** (0.11 g, 0.55 mmol) as a clear colourless oil and as a 1 : 1 mixture of two diastereomers; ν_{\max} (film)/cm⁻¹ 3429, 2931, 2858, 1645, 1472, 1428, 1331, 1008, 905, 823, 739, 702; δ_{H} (300 MHz, CDCl₃) \ddagger 1.21 (1.5H, d, *J* 6.2 Hz, Me), 1.30 (1.5H, d, *J* 6.2 Hz, Me⁺), 1.22–1.28 (1H, m, H8A), 1.57–1.72 (7H, m, H1', H2', H3, H8B), 1.97–2.31 (4H, m, H4, H9), 3.66 (2H, t, *J* 6.0 Hz, H3'), 4.05 (1H, dddd, *J* 10.7, 8.7, 4.9, 2.2 Hz, H7), 4.19 (1H, qdd, *J* 6.4, 6.4, 2.2 Hz, H2); δ_{C} (75.5 MHz, CDCl₃) 21.1 (CH₃, Me⁺), 22.5 (CH₃, Me⁺), 29.7 (CH₂, C2'), 30.4 (CH₂, C8), 32.1 (CH₂, C3), 32.7 (CH₂, C1'), 35.4 (CH₂, C4), 35.6 (CH₂, C4*), 36.1 (CH₂, C9), 36.5 (CH₂, C9*), 63.0 (CH₂, C3'), 74.2 (CH, C2⁺), 76.0 (CH, C2⁺), 78.0 (CH, C7⁺), 80.0 (CH, C7⁺), 114.3 (quat., C5⁺), 114.7 (quat., C5⁺); *m/z* (CI, NH₃) 201 (MH⁺, 100%), 183 (56), 141 (29), 127 (6), 112 (7), 111 (6), 98 (4); HRMS (CI): Found MH⁺, 201.1490; C₁₁H₂₁O₃ requires 201.1491.

(2''S,5''R,7''S) and (2''S,5''S,7''S)-5-(3'-(2''-Methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)-propylsulfanyl)-1-phenyl-1H-tetrazole (26) and (27)

To a stirred solution of alcohols **24** and **25** (1 : 1 mixture) (0.22 g, 0.55 mmol) in tetrahydrofuran (2 mL) under an atmosphere of nitrogen at room temperature was added triphenylphosphine (0.16 g, 0.61 mmol) and 1-phenyl-1H-tetrazole-5-thiol (0.11 g, 0.61 mmol). The mixture was cooled to 0 °C and a solution of diethyl azodicarboxylate (0.10 mL, 0.51 mmol) in tetrahydrofuran (1 mL) added dropwise *via* syringe. The solution was warmed to room temperature over 15 h then the solvent removed at reduced pressure. The residue was treated with a solution of hexane–ethyl acetate (5 : 1, v/v, 5 mL). The resultant precipitate was removed by filtration and the precipitate washed twice with hexane–ethyl acetate (5 : 1, v/v, 10 mL). The solvent was removed under reduced pressure and the resultant residue purified by flash column chromatography using hexane–diethyl ether (9 : 1) to yield the *title compounds* **26** and **27** (0.15 g, 78%) as a pale yellow oil and as a 1 : 1 mixture of diastereomers; ν_{\max} (film)/cm⁻¹ 2972, 2945, 2871, 2242, 1597, 1500, 1458, 1387, 1243, 1073, 1058, 1014, 910, 761; δ_{H} (300 MHz, CDCl₃) \ddagger 1.14 (1.5H, d, *J* 6.2 Hz, Me⁺), 1.19 (1.5H, d, *J* 6.2 Hz, Me⁺), 1.34–1.44 (2H, m, H3''A, H8''A), 1.57–1.67 (2H, m, H3'), 1.80–1.87 (2H, m, H2'), 1.89–2.03 (6H, m, H3''B, H4'', H8''B, H9''), 3.38 (2H, t, *J* 7.0 Hz, H1'), 3.90–3.94 (0.5H, m, H7''⁺), 3.99–4.06 (0.5H, m, H7''⁺), 4.11–4.24 (1H, m, H2''), 7.48–7.51 (5H, m, Ph, *o*, *m*, *p*); δ_{C} (75.5 MHz, CDCl₃) \ddagger 20.9 (CH₃, Me⁺), 22.8 (CH₃, Me⁺), 25.5 (CH₂, C2'), 25.7 (CH₂, C2'*), 30.1 (CH₂, C8''), 30.5 (CH₂, C8''*), 32.0 (CH₂, C3''), 32.4 (CH₂, C3''*), 33.2 (CH₂, C1'), 34.2 (CH₂, C3'), 35.2 (CH₂, C4''), 35.4 (CH₂, C4''*), 35.8 (CH₂, C9''), 36.3 (CH₂, C9''*), 73.9 (CH, C2''⁺), 75.7 (CH, C2''⁺), 77.1 (CH, C7''⁺), 78.8 (CH, C7''⁺), 114.3 (quat., C5''⁺), 114.7 (quat., C5''⁺), 123.6 (CH, Ph, *m*), 129.6 (CH, Ph, *p*), 129.9 (CH, Ph, *o*), 133.5 (quat., Ph), 154.2 (quat., C5); *m/z* (CI, NH₃) 361 (MH⁺, 100%), 343 (14), 215 (6), 141 (11), 111 (10), 100 (9), 83

(12); HRMS (CI): Found MH⁺, 361.1696; C₁₈H₂₅N₄O₂S requires 361.1698.

(2''S,5''R,7''S) and (2''S,5''S,7''S)-5-(3'-(2''-Methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)-propylsulfanyl)-1-phenyl-1H-tetrazole (6) and (7)

To a solution of sulfides **26** and **27** (1 : 1 mixture) (0.15 g, 0.42 mmol) in dichloromethane (2 mL) was added sodium bicarbonate (0.18 g, 2.08 mmol), followed by a solution of *m*-chloroperoxybenzoic acid (0.18 g, 1.04 mmol) in dichloromethane (2 mL) dropwise *via* syringe. The mixture was stirred under an atmosphere of nitrogen at room temperature for 24 h then a solution of saturated aqueous sodium bicarbonate (2.5 mL) and sodium thiosulfate (2.5 mL) added dropwise. The layers were separated and the aqueous layer extracted with dichloromethane (2 × 10 mL). The combined organic layers were dried over potassium carbonate and the solvent removed under reduced pressure. The crude oil was purified by flash column chromatography using hexane–diethyl ether (9 : 1) as eluent to yield the *title compounds* **6** and **7** (0.12 g, 71%) as a clear colourless oil and as a 1 : 1 mixture of diastereomers; ν_{\max} (film)/cm⁻¹ 2926, 2872, 1635, 1595, 1497, 1461, 1337, 1151, 916, 867, 762, 731, 688; δ_{H} (300 MHz, CDCl₃) \ddagger 1.19 (1.5H, d, *J* 6.2 Hz, Me⁺), 1.24 (1.5H, d, *J* 6.2 Hz, Me⁺), 1.23–1.26 (1H, m, H8''A), 1.39–1.52 (2H, m, H3''A, H8''B), 1.63–1.77 (3H, m, H3', H4''A), 1.84–1.91 (1H, m, H9''A), 1.93–2.15 (5H, m, H2', H3''B, H4''B, H9''B), 3.73–3.82 (2H, m, H1'), 3.94–3.98 (0.5H, m, H7''⁺), 4.01–4.07 (0.5H, m, H7''⁺), 4.10–4.21 (1H, m, H2''), 7.56–7.60 (3H, m, Ph, *m* and *p*), 7.62–7.68 (2H, m, Ph, *o*); δ_{C} (75.5 MHz, CDCl₃) \ddagger 19.0 (CH₂, C2'), 19.2 (CH₂, C2'*), 21.0 (CH₃, Me⁺), 22.5 (CH₃, Me⁺), 30.2 (CH₂, C8''), 30.5 (CH₂, C8''*), 32.0 (CH₂, C3''), 32.5 (CH₂, C3''*), 33.6 (CH₂, C3'), 35.2 (CH₂, C4''), 35.4 (CH₂, C4''*), 35.9 (CH₂, C9''), 36.4 (CH₂, C9''*), 55.9 (CH₂, C1'), 55.9 (CH₂, C1'*), 74.0 (CH, C2''⁺), 76.0 (CH, C2''⁺), 76.8 (CH, C7''⁺), 78.6 (CH, C7''⁺), 114.6 (quat., C5''⁺), 114.9 (quat., C5''⁺), 125.0 (CH, Ph, *m*), 129.6 (CH, Ph, *p*), 131.3 (CH, Ph, *o*), 133.0 (quat., Ph), 153.4 (quat., C5); *m/z* (CI, NH₃) 393 (MH⁺, 100%), 375 (28), 183 (10), 119 (15), 111 (26), 89 (23), 83 (31); HRMS (CI): Found MH⁺, 393.1601; C₁₈H₂₅N₄O₄S requires 393.1597.

(3'E,3S,2''S,5''S,7''S)-, (3'E,3S,2''S,5''R,7''S)-, (3'Z,3S,2''S,5''S,7''S)- and (3'Z,3S,2''S,5''R,7''S)-5,7-Dimethoxy-3-[6'-(2''-methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)hex-3'-en-1'-yl]-3H-isobenzofuran-1-one (28) and (29)

To a solution of sulfones **6** and **7** (30 mg, 0.08 mmol, 1 : 1) in tetrahydrofuran (1 mL), under an atmosphere of nitrogen at –78 °C, was added potassium hexamethyldisilazide (0.20 mL, 0.5 M in toluene, 0.10 mmol) dropwise. The mixture was stirred for 20 min at –78 °C then a solution of aldehyde **5a** (19 mg, 0.08 mmol) in tetrahydrofuran (1 mL) added. The mixture was stirred for 1.5 h at –78 °C then 1 h at rt. Diethyl ether (10 mL) was added followed by saturated aqueous sodium chloride (10 mL). The layers were separated and the aqueous layer washed with diethyl ether (2 × 10 mL). The combined organic layers were dried over potassium carbonate and the solvent removed under reduced pressure. The crude oil was purified by flash column chromatography using hexane–diethyl ether (1 : 1) as eluent to

afford the *title compounds* **28** and **29** (28 mg, 84%) as a colourless oil and as a 1 : 1 mixture of diastereomers; ν_{\max} (film)/ cm^{-1} 2971, 2248, 2091, 1743, 1614, 1458, 1337, 1217, 1158, 1028, 910, 837, 730; δ_{H} (300 MHz, CDCl_3) \ddagger 1.19 (1.5H, d, J 6.2 Hz, ((*E*)-Me \ddagger and (*Z*)-Me \ddagger), 1.30 (1.5H, d, J 6.2 Hz, ((*E*)-Me ϕ and (*Z*)-Me ϕ), 1.40–1.52 (2H, m, H6'), 1.69–1.81 (3H, m, H3'', H8''A), 1.83–1.91 (1H, m, H8''B), 1.95–2.17 (6H, m, H1', H4'', H9''), 2.27–2.48 (4H, m, (*E*)-H2' and (*Z*)-H2', (*E*)-H5' and (*Z*)-H5'), 3.89 (3H, s, OMe), 3.89–3.99 (2H, m, H7''), 3.95 (3H, s, OMe), 4.01–4.10 (1H, m, H2'' ϕ), 4.13–4.20 (1H, m, H2'' \ddagger), 5.28, 5.35 (each 1H, each dd, J 8.5, 3.1 Hz, H3), 5.50–5.62 (2H, m, (*E*)-H3' and (*Z*)-H3', (*E*)-H4' and (*Z*)-H4'), 6.40–6.42 (1H, m, H6), 6.42–6.43 (1H, m, H4); δ_{C} (75.5 MHz, CDCl_3) 21.1 (CH $_3$, Me \ddagger), 23.1 (CH $_3$, Me ϕ), 24.0 (CH $_2$, (*Z*)-C2'), 24.1 (CH $_2$, (*Z*)-C5'), 29.7 (CH $_3$, (*E*)-C2'), 30.2 (CH $_2$, (*E*)-C5'), 30.2 (CH $_2$, C8'' \ddagger), 30.5 (CH $_2$, C8'' ϕ), 32.2 (CH $_2$, C3'' \ddagger), 32.6 (CH $_2$, C3'' ϕ), 34.6, 34.7 (CH $_2$, C1'), 35.5 (CH $_2$, C4'' \ddagger), 35.6 (CH $_2$, C9'' \ddagger), 36.0 (CH $_2$, C4'' ϕ), 36.4 (CH $_2$, C9'' ϕ), 38.9 (CH $_2$, C6'), 55.9 (CH $_3$, OMe), 56.0 (CH $_3$, OMe), 74.1, 75.9, 76.0 (CH, C2''), 77.2, 78.5, 78.6 (CH, C7''), 79.2 (CH, C3), 97.4 (CH, C6), 98.9 (CH, C4), 106.8 (quat, C7a), 114.4 (quat, C5'' ϕ), 114.9 (quat, C5'' \ddagger), 123.4, 123.6 (CH, C3'), 126.1, 126.3 (CH, C4'), 154.7 (quat, C3a), 159.7 (quat, C7), 166.7 (quat, C5), 166.8 (quat, C1); m/z (EI $^+$) (MH $^+$, 96%), 399 (38), 305 (12), 219 (7), 193 (12), 154 (100), 85 (9); HRMS (EI $^+$): Found M $^+$, 416.2183, C $_{24}$ H $_{32}$ O $_6$ requires 416.2193.

(3*S*,2''*S*,5''*S*,7''*S*)- and (3*S*,2''*S*,5''*R*,7''*S*)-5,7-Dimethoxy-3-[6'-(2''-methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)hex-1''-yl]-3*H*-isobenzofuran-1-one (1a) [ent-CJ-12,954] and (2a) [ent-CJ-13,014]

To a solution of the above alkenes (2 mg, 0.01 mmol) in tetrahydrofuran : methanol (1 : 1, 2.0 mL) was added potassium carbonate (2 mg, 0.01 mmol) and platinum(IV) oxide (1 mg, catalytic) and the mixture stirred under a hydrogen atmosphere for 4 h. The mixture was filtered through a pad of silica and Celite $^{\text{®}}$ and the solvent removed under reduced pressure. The clear oil was purified by flash column chromatography using dichloromethane-acetone (99 : 1–95 : 5) as eluent to afford the *title compounds* **1a** and **2a** (1.7 mg, 85%) as a clear colourless oil and as a 1 : 1 mixture of diastereomers; $[\alpha]_{\text{D}} -38.0$ (c 0.48, CHCl_3); ν_{\max} (film)/ cm^{-1} 2929, 2856, 1755, 1614, 1462, 1337, 1217, 1158, 1104, 1030, 918, 837, 731, 690; δ_{H} (400 MHz, CDCl_3) \ddagger 1.20 (1.5H, d, J 6.2 Hz, Me \ddagger), 1.28 (1.5H, d, J 6.2 Hz, Me ϕ), 1.25–1.35 (4H, m, H3', H5'), 1.39–1.49 (4H, m, H2', H4'), 1.61–1.73 (3H, m, H6', H8''A), 1.83–1.91 (1H, m, H8''B), 1.92–1.97 (2H, m, H3''), 2.00–2.07 (4H, m, H4'', H9''), 2.09–2.14 (2H, m, H1'), 3.89 (3H, s, OMe), 3.90–3.92 (0.5H, m, H7'' ϕ), 3.94 (3H, s, OMe), 3.99–4.04 (0.5H, m, H7'' \ddagger), 4.07–4.12 (0.5H, m, H2'' ϕ), 4.16–4.23 (0.5H, m, H2'' \ddagger), 5.29 (1H, dd, J 8.2, 3.6 Hz, H3), 6.40 (1H, d, J 1.7 Hz, H6), 6.41 (1H, d, J 1.7 Hz, H4); δ_{C} (100 MHz, CDCl_3) 21.1 (CH $_3$, Me \ddagger), 23.0 (CH $_3$, Me ϕ), 24.6 (CH $_2$, C2'), 25.7, 25.9 (CH $_2$, C5'), 29.3, 29.4 (CH $_2$, C3'), 29.7 (CH $_2$, C4'), 30.2 (CH $_2$, C8'' \ddagger), 30.7 (CH $_2$, C8'' ϕ), 32.2 (CH $_2$, C3'' \ddagger), 32.6 (CH $_2$, C3'' ϕ), 34.8 (CH $_2$, C1'), 35.6 (CH $_2$, C6'' \ddagger), 35.7 (CH $_2$, C4'' \ddagger), 36.1 (CH $_2$, C4'' ϕ), 36.5 (CH $_2$, C9'' \ddagger), 37.3 (CH $_2$, C6'' ϕ), 55.9 (CH $_3$, OMe), 56.0 (CH $_3$, OMe), 74.0 (CH, C2'' \ddagger), 75.8 (CH, C2'' ϕ), 78.1 (CH, C7'' \ddagger), 79.9 (CH, C7'' ϕ), 79.9 (CH, C3), 97.3 (CH, C6), 98.6 (CH, C4), 106.9 (quat, C7a), 114.3 (quat, C5'' ϕ), 114.7 (quat, C5'' \ddagger), 155.2 (quat, C3a), 159.6 (quat, C7), 166.6 (quat, C5), 168.6

(quat, C1); m/z (EI $^+$) 418 (M $^+$, 3%), 361 (26), 320 (24), 278 (9), 207 (16), 193 (35), 141 (100), 112 (13), 85 (24), 55 (9); HRMS (EI $^+$): Found MH $^+$, 418.2340, C $_{24}$ H $_{35}$ O $_6$ requires 418.2355.

(3'*E*,3*R*,2''*S*,5''*S*,7''*S*)-, (3'*E*,3*R*,2''*S*,5''*R*,7''*S*)-, (3'*Z*,3*R*,2''*S*,5''*S*,7''*S*)- and (3'*Z*,3*R*,2''*S*,5''*R*,7''*S*)-5,7-Dimethoxy-3-[6'-(2''-methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)hex-3''-en-1''-yl]-3*H*-isobenzofuran-1-one (32) and (33)

To a solution of sulfones **6** and **7** (70 mg, 0.18 mmol, 1 : 1) in tetrahydrofuran (2 mL) under an atmosphere of nitrogen at $-78\text{ }^{\circ}\text{C}$ was added potassium hexamethyldisilazide (0.46 mL, 0.5 M in toluene, 0.23 mmol) and stirred for 20 min. A solution of aldehyde **5b** (45 mg, 0.18 mmol) in tetrahydrofuran (2 mL) was added to the mixture and then stirred at $-78\text{ }^{\circ}\text{C}$ for 1 h, before being warmed to rt and stirred for 1 h. Saturated aqueous sodium chloride (10 mL) was added to the mixture, followed by diethyl ether (20 mL), and the layers separated. The aqueous layer was extracted with diethyl ether (2 \times 20 mL), and the combined organic extracts were dried over potassium carbonate and the solvent removed under reduced pressure. The crude oil was purified by flash column chromatography using dichloromethane-methanol (99 : 1), then hexane-diethyl ether (1 : 1) as eluent to afford the *title compounds* **32** and **33** (57 mg, 76%) as a clear colourless oil and as a 1 : 1 mixture of diastereomers; ν_{\max} (film)/ cm^{-1} 2966, 2932, 2248, 1755, 1613, 1494, 1461, 1338, 1217, 1158, 1056, 1030, 969, 918, 838, 731; δ_{H} (300 MHz, CDCl_3) \ddagger 1.18 (1.5H, d, J 6.2 Hz, ((*E*)-Me \ddagger and (*Z*)-Me \ddagger), 1.26 (1.5H, d, J 6.2 Hz, ((*E*)-Me ϕ and (*Z*)-Me ϕ), 1.41–1.49 (2H, m, H6'), 1.51–1.65 (1H, m, H8''A), 1.67 (3H, m, H8''B, H3''), 1.94–2.11 (8H, m, H1', H4'', H5', H9''), 2.13–2.24 (2H, m, (*E*)-H2' and (*Z*)-H2'), 3.87 (3H, s, OMe), 3.87–3.89 (1H, m, H7'' ϕ), 3.92 (3H, s, OMe), 3.92–3.98 (1H, m, H7'' \ddagger), 4.00–4.08 (1H, m, H2'' ϕ), 4.09–4.21 (1H, m, H2'' \ddagger), 5.27 (1H, dd, J 8.5, 3.3 Hz, H3), 5.35–5.53 (2H, m, (*E*)-H3' and (*Z*)-H3', (*E*)-H4' and (*Z*)-H4'), 6.39 (2H, s, H4, H6); δ_{C} (75.5 MHz, CDCl_3) 21.1 (CH $_3$, Me \ddagger), 22.6 (CH $_2$, (*Z*)-C2'), 23.0 (CH $_3$, Me ϕ), 23.6 (CH $_2$, (*Z*)-C5'), 27.8 (CH $_3$, (*E*)-C2'), 28.8 (CH $_2$, (*E*)-C5'), 30.1, 30.3, 30.6, 30.7 (CH $_2$, C8'' \ddagger), 32.2 (CH $_2$, C3'' \ddagger), 32.6 (CH $_2$, C3'' ϕ), 34.8 (CH $_2$, C1'), 35.4 (CH $_2$, C6'' \ddagger), 35.5 (CH $_2$, C4'' \ddagger), 35.6 (CH $_2$, C9'' \ddagger), 36.0 (CH $_2$, C4'' ϕ), 36.4 (CH $_2$, C9'' ϕ), 37.1 (CH $_2$, C6'' ϕ), 55.9 (CH $_3$, OMe), 55.9 (CH $_3$, OMe), 74.0 (CH, C2'' \ddagger), 75.8 (CH, C2'' ϕ), 77.5 (CH, C7'' \ddagger), 79.1 (CH, C7'' ϕ), 79.2 (CH, C3), 97.4 (CH, C6), 98.7 (CH, C4), 106.9 (quat, C7a), 114.3 (quat, C5'' ϕ), 114.7 (quat, C5'' \ddagger), 128.2, 128.4 (CH, C3'), 131.5, 131.7 (CH, C4'), 155.1 (quat, C3a), 159.6 (quat, C7), 166.6 (quat, C5), 168.4 (quat, C1); m/z (FAB $^+$) (MH $^+$, 96%), 399 (38), 305 (12), 219 (7), 193 (12), 154 (100), 85 (9); HRMS (FAB $^+$): Found MH $^+$, 417.2268, C $_{24}$ H $_{33}$ O $_6$ requires 417.2277.

(3*R*,2''*S*,5''*R*,7''*S*)- and (3*R*,2''*S*,5''*S*,7''*S*)-5,7-Dimethoxy-3-[6'-(2''-methyl-1'',6''-dioxaspiro[4.4]non-7''-yl)hex-1''-yl]-3*H*-isobenzofuran-1-one (1b) and (2b)

To a solution of the above alkenes (20 mg, 0.48 mmol) in tetrahydrofuran : methanol (1 : 1, 4 mL) was added potassium carbonate (25 mg, 0.18 mmol) and platinum(IV) oxide (2 mg) and the mixture stirred under an atmosphere of hydrogen for 4 h. The mixture was filtered through a pad of silica and Celite $^{\text{®}}$ and the solvent removed under reduced pressure to afford the

title compounds 1b and 2b (18 mg, 90%) as a colourless oil and as a 1 : 1 mixture of diastereomers; $[\alpha]_{\text{D}}^{25} +36.4$ (c 0.50, CHCl_3); ν_{max} (film)/ cm^{-1} 2931, 2857, 1755, 1613, 1494, 1462, 1337, 1217, 1159, 1054, 1030, 918, 837, 731, 690; δ_{H} (300 MHz, CDCl_3) \ddagger 1.19 (1.5H, d, J 6.2 Hz, Me^{\ddagger}), 1.26 (1.5H, d, J 6.2 Hz, Me^{ϕ}), 1.23–1.36 (4H, m, $\text{H}3'$, $\text{H}5'$), 1.38–1.49 (6H, m, $\text{H}2'$, $\text{H}4'$, $\text{H}6'$), 1.62–1.72 (2H, m, $\text{H}1''\text{A}$, $\text{H}8''\text{A}$), 1.88–1.90 (1H, m, $\text{H}8''\text{B}$), 1.92–1.97 (2H, m, $\text{H}3''$), 1.99–2.05 (3H, m, $\text{H}4''\text{A}$, $\text{H}9''$), 2.09–2.14 (2H, m, $\text{H}1''\text{B}$, $\text{H}4''\text{B}$), 3.87 (3H, s, OMe), 3.88–3.90 (0.5H, m, $\text{H}7''^{\phi}$), 3.92 (3H, s, OMe), 3.96–4.03 (0.5H, m, $\text{H}7''^{\ddagger}$), 4.05–4.08 (0.5H, m, $\text{H}2''^{\phi}$), 4.11–4.21 (0.5H, m, $\text{H}2''^{\ddagger}$), 5.26 (1H, dd, J 7.5, 3.8 Hz, $\text{H}3$), 6.38 (1H, s, $\text{H}6$), 6.41 (1H, s, $\text{H}4$); δ_{C} (75.5 MHz, CDCl_3) 21.1 (CH_3 , Me^{\ddagger}), 22.9 (CH_3 , Me^{ϕ}), 24.5, 24.6 (CH_2 , $\text{C}2'$), 25.6, 25.9 (CH_2 , $\text{C}5'$), 29.2, 29.4 (CH_2 , $\text{C}3'$), 29.6 (CH_2 , $\text{C}4'$), 30.2 (CH_2 , $\text{C}8''^{\ddagger}$), 30.7 (CH_2 , $\text{C}8''^{\phi}$), 32.2 (CH_2 , $\text{C}3''^{\ddagger}$), 32.6 (CH_2 , $\text{C}3''^{\phi}$), 34.8 (CH_2 , $\text{C}1'$), 35.6 (CH_2 , $\text{C}6''^{\ddagger}$), 35.7 (CH_2 , $\text{C}4''^{\ddagger}$), 36.1 (CH_2 , $\text{C}4''^{\phi}$), 36.4 (CH_2 , $\text{C}9''$), 37.3 (CH_2 , $\text{C}6''^{\phi}$), 55.9 (CH_3 , OMe), 55.9 (CH_3 , OMe), 74.0 (CH , $\text{C}2''^{\ddagger}$), 75.7 (CH , $\text{C}2''^{\phi}$), 78.0 (CH , $\text{C}7''^{\ddagger}$), 79.9 (CH , $\text{C}7''^{\phi}$), 79.9 (CH , $\text{C}3$), 97.4 (CH , $\text{C}6$), 98.6 (CH , $\text{C}4$), 106.9 (quat, $\text{C}7\text{a}$), 114.2 (quat, $\text{C}5''^{\phi}$), 114.7 (quat, $\text{C}5''^{\ddagger}$), 155.1 (quat, $\text{C}3\text{a}$), 159.6 (quat, $\text{C}7$), 166.6 (quat, $\text{C}5$), 168.4 (quat, $\text{C}1$); m/z (FAB^+) 419 (MH^+ , 81%), 361 (5), 320 (6), 207 (7), 193 (10), 154 (100), 120 (12), 111 (11) (9); HRMS (FAB^+): Found MH^+ , 419.2446, $\text{C}_{24}\text{H}_{35}\text{O}_6$ requires 419.2434.

Acknowledgements

We thank Dr Shinichi Sakemi (Pfizer R&D, Groton, USA) for kindly providing us with samples of the natural products CJ-12,954 and CJ-13,014 for comparative purposes. CJB gratefully acknowledged the award of a Bright Futures Top Achiever Doctoral Scholarship.

References

- 1 B. J. Marshall and J. R. Warren, *Lancet*, 1984, **323**, 1311.
- 2 C. Montecucco and M. D. Bernard, *Microbes Infect.*, 2003, **5**, 715.
- 3 J. Mackay, A. Jemal, N. C. Lee and D. M. Parkin, *The Cancer Atlas*, American Cancer Society, New York, 2nd edn, 2006.
- 4 C. Stoicov, R. Saffari, X. Cai, C. Hasyagar and J. Houghton, *Gene*, 2004, **341**, 1.
- 5 E. M. F. Muri and J. S. Williamson, *Mini-Rev. Med. Chem.*, 2004, **4**, 201.
- 6 J. H. Walsh and W. L. Peterson, *New Engl. J. Med.*, 1995, **333**, 984; B. Rathbone, *Scrip Magazine*, 1993, 25.
- 7 K. A. Dekker, T. Inagake, T. D. Gootz, K. Kaneda, E. Nomura, T. Sakakibara, S. Sakemi, Y. Sugie, Y. Yamauchi, N. Yoshikawa and N. J. Kojima, *J. Antibiot.*, 1997, **50**, 833.
- 8 A. Arnone, G. Assante, G. Nasini and O. Vajna dePava, *Phytochemistry*, 1990, **29**, 613; M. A. Gaudliana, L. H. Huang, T. Kaneko and P. C. Watts, *PCT Int. Appl.*, 1996, W0 9605204; CAN 125:58200.
- 9 M. Mondal and N. P. Argade, *Tetrahedron Lett.*, 2004, **45**, 5693.
- 10 S. Dallavalle, R. Nannei, L. Merlini, A. Bava and G. Nasini, *Synlett*, 2005, **17**, 2676.
- 11 M. A. Brimble, C. L. Flowers, J. K. Hutchinson, J. E. Robinson and M. Sidford, *Tetrahedron*, 2005, **61**, 10036.
- 12 J. E. Robinson and M. A. Brimble, *Chem. Commun.*, 2005, 1560; J. E. Robinson and M. A. Brimble, *Org. Biomol. Chem.*, 2007, DOI: 10.1039/b708265g.
- 13 A. Bava, M. Clericuzio, G. Giannini, L. Malpezzi, S. V. Meille and G. Nasini, *Eur. J. Org. Chem.*, 2005, **11**, 2292.
- 14 R. Nannei, S. Dallavalle, L. Merlini, A. Bava and G. Nasini, *J. Org. Chem.*, 2006, **71**, 6277.
- 15 For a preliminary communication of this work see: M. A. Brimble and C. J. Bryant, *Chem. Commun.*, 2006, 4506.
- 16 Z. Wang, B. La, J. M. Fortunak, X.-J. Meng and G. W. Kabalka, *Tetrahedron Lett.*, 1998, **39**, 5501.
- 17 (a) E. J. Corey, R. K. Bakshi, S. Shibata, C.-P. Chen and V. K. Singh, *J. Am. Chem. Soc.*, 1987, **109**, 7925; (b) E. J. Corey, S. Shibata and R. K. Bakshi, *J. Org. Chem.*, 1988, **53**, 2861.
- 18 A. S. Cotterill, M. Gill, A. Gimenez and N. M. Milanovic, *J. Chem. Soc., Perkin Trans. 1*, 1994, 3269.
- 19 For a review on the heterocycle-activated modified Julia reaction see: P. R. Blakemore, *J. Chem. Soc., Perkin Trans. 1*, 2002, 2563. For examples of the use of the heterocycle-activated modified Julia reaction using heterocyclic sulfones bearing a spiroacetal functionality see: S. V. Ley, A. C. Humphries, H. Eick, R. Downham, A. R. Ross, R. J. Boyce, J. B. J. Pavey and J. Pietruszka, *J. Chem. Soc., Perkin Trans. 1*, 1998, 3907; T. Shimizu, T. Masuda, K. Hiramoto and T. Nakata, *Org. Lett.*, 2000, **2**, 2153.
- 20 P. R. Blakemore, W. J. Cole, P. J. Kocienski and A. Morley, *Synlett*, 1998, 26.
- 21 F. Freeman, D. S. H. L. Kim and E. Rodriguez, *J. Org. Chem.*, 1992, **57**, 1722.
- 22 Y. Yuasa, J. Ando and S. Shibuya, *J. Chem. Soc., Perkin Trans. 1*, 1996, 793.
- 23 W. R. Roush, L. K. Hoong, M. A. J. Palmer, J. A. Straub and A. D. Palkowitz, *J. Org. Chem.*, 1990, **55**, 4117.
- 24 P. E. van Rijn, S. Mommers, R. G. Visser, H. D. Verkruysse and L. Brandsma, *Synthesis*, 1981, 451.
- 25 E. M. Carreira and J. Du Bois, *J. Am. Chem. Soc.*, 1994, **116**, 10825.
- 26 For reviews on the anomeric effect see: P. Deslongchamps, *Stereoelectronic Effects in Organic Chemistry*, Pergamon Press, New York, 1983; A. J. Kirby, *The Anomeric Effect and Related Stereoelectronic Effects at Oxygen*, Springer-Verlag, New York, 1983.
- 27 (a) J. B. Baudin, G. Hareau, S. A. Julia and O. Ruel, *Tetrahedron Lett.*, 1991, **32**, 1175; (b) P. J. Kocienski, A. Bell and P. R. Blakemore, *Synlett*, 2000, 365; (c) J. B. Baudin, G. Hareau, S. A. Julia, R. Lorne and O. Ruel, *Bull. Soc. Chim. Fr.*, 1993, **130**, 856.
- 28 D. Bondar and L. A. Paquette, *Org. Lett.*, 2005, **7**, 1813.